Premium
Evaluation of the effect of azapropazone on neutrophil migration in anaesthetized swine using a multichamber blister suction technique
Author(s) -
Mousa S.A.,
Brown R.,
Chan Y.,
Hsieh J.,
Smith R.D.
Publication year - 1990
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1990.tb14686.x
Subject(s) - chemotaxis , pharmacology , in vivo , myeloperoxidase , chemistry , neutrophile , inflammation , medicine , immunology , biology , biochemistry , receptor , microbiology and biotechnology
1 The purpose of this study was to determine the in vivo inhibitory efficacy of azopropazone on neutrophil migration. The effects of azapropazone given at a dose of 100 mg kg −1 i.v. every 2 h on the neutrophil migration into skin inflammation sites (blister fluid) as well as into an autologous serum (± chemoattractant) placed above the blister surface (2nd chamber) were determined. 2 Azapropazone treatment schedule maintained blood levels at 70–100 μg ml −1 throughout the time course (360 min) of the experiment. 3 Azapropazone significantly inhibited (48 ± 6%) neutrophil migration into the blister fluid (as evident from the decrease in myeloperoxidase activity). 4 Azapropazone significantly inhibited the neutrophil migration into the autologous serum either with (65 ± 5%) or (35 ± 6%) without the chemoattractant, formyl‐methionyl‐leucyl‐phenylalanine (FMLP). The chemoattractant, FMLP, markedly increased neutrophil migration into the autologous serum by approximately 1.5 to 2 times the non‐FMLP treated group. Azapropazone was more efficacious in inhibiting the neutrophil migration in the presence of FMLP than in its absence. 5 We conclude that azapropazone is an effective inhibitor of neutrophil migration into topically inflamed sites in anaesthetized swine.